Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Mar;57(3):548-562.
doi: 10.1038/s41588-025-02074-9. Epub 2025 Mar 6.

Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk

Seung Hoan Choi #  1   2 Sean J Jurgens #  1   3 Ling Xiao  1   4 Matthew C Hill  1   4 Christopher M Haggerty  5 Garðar Sveinbjörnsson  6 Valerie N Morrill  1 Nicholas A Marston  7   8 Lu-Chen Weng  1   4 James P Pirruccello  1   4   9 David O Arnar  6   10   11 Daniel Fannar Gudbjartsson  6   12 Helene Mantineo  1 Aenne S von Falkenhausen  13   14 Andrea Natale  15 Arnljot Tveit  16 Bastiaan Geelhoed  17 Carolina Roselli  1 David R Van Wagoner  18 Dawood Darbar  19 Doreen Haase  20 Elsayed Z Soliman  21 Giovanni E Davogustto  22 Goo Jun  23 Hugh Calkins  24 Jeffrey L Anderson  25   26 Jennifer A Brody  27 Jennifer L Halford  1   4 John Barnard  28 John E Hokanson  29 Jonathan D Smith  18 Joshua C Bis  27 Kendra Young  29 Linda S B Johnson  30 Lorenz Risch  31   32 Lorne J Gula  33 Lydia Coulter Kwee  34 Mark D Chaffin  1 Michael Kühne  35 Michael Preuss  36 Namrata Gupta  37 Navid A Nafissi  38 Nicholas L Smith  39   40 Peter M Nilsson  41   42 Pim van der Harst  17   43 Quinn S Wells  22   44 Renae L Judy  45   46 Renate B Schnabel  20   47   48 Renee Johnson  49   50 Roelof A J Smit  36 Stacey Gabriel  37 Stacey Knight  25   51 Tetsushi Furukawa  52 Thomas W Blackwell  53 Victor Nauffal  1   4 Xin Wang  1   4 Yuan-I Min  54 Zachary T Yoneda  22 Zachary W M Laksman  55 Connie R Bezzina  3 Alvaro Alonso  56 Bruce M Psaty  27   39 Christine M Albert  57 Dan E Arking  58 Dan M Roden  44 Daniel I Chasman  37   59 Daniel J Rader  60 David Conen  61 David D McManus  62 Diane Fatkin  49   50   63 Emelia J Benjamin  64   65 Eric Boerwinkle  66 Gregory M Marcus  9 Ingrid E Christophersen  16   67 J Gustav Smith  68   69 Jason D Roberts  33   70 Laura M Raffield  71 M Benjamin Shoemaker  22 Michael H Cho  72 Michael J Cutler  25 Michiel Rienstra  17 Mina K Chung  73 Morten S Olesen  74   75 Moritz F Sinner  13   14 Nona Sotoodehnia  27 Paulus Kirchhof  20   47   48   76 Ruth J F Loos  36   77 Saman Nazarian  78 Sanghamitra Mohanty  15   79 Scott M Damrauer  45   46   60 Stefan Kaab  13   14 Susan R Heckbert  40   80 Susan Redline  81 Svati H Shah  38 Toshihiro Tanaka  82   83 Yusuke Ebana  84 Regeneron Genetics CenterNHLBI Trans-Omics for Precision Medicine (TOPMed) ConsortiumHilma Holm  6 Kari Stefansson  6   11 Christian T Ruff  7   8 Marc S Sabatine  7   8 Kathryn L Lunetta  2   64 Steven A Lubitz  1   4   85 Patrick T Ellinor  86   87   88
Collaborators, Affiliations
Meta-Analysis

Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk

Seung Hoan Choi et al. Nat Genet. 2025 Mar.

Abstract

Atrial fibrillation (AF) is a prevalent and morbid abnormality of the heart rhythm with a strong genetic component. Here, we meta-analyzed genome and exome sequencing data from 36 studies that included 52,416 AF cases and 277,762 controls. In burden tests of rare coding variation, we identified novel associations between AF and the genes MYBPC3, LMNA, PKP2, FAM189A2 and KDM5B. We further identified associations between AF and rare structural variants owing to deletions in CTNNA3 and duplications of GATA4. We broadly replicated our findings in independent samples from MyCode, deCODE and UK Biobank. Finally, we found that CRISPR knockout of KDM5B in stem-cell-derived atrial cardiomyocytes led to a shortening of the action potential duration and widespread transcriptomic dysregulation of genes relevant to atrial homeostasis and conduction. Our results highlight the contribution of rare coding and structural variants to AF, including genetic links between AF and cardiomyopathies, and expand our understanding of the rare variant architecture for this common arrhythmia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: P.T.E. has received sponsored research support from Bayer AG, Bristol Myers Squibb, Pfizer and Novo Nordisk, and he has consulted for Bayer. S.A.L. is a full-time employee of Novartis Institutes of BioMedical Research as of 18 July 2022. S.A.L. previously received sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit, Medtronic, Premier and IBM and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences and Invitae. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. M.H.C. has received grant funding from GSK and Bayer, and speaking or consulting fees from AstraZeneca, Illumina and Genentech. C.M.H. receives research support from Tempus Labs, outside the scope of the present work. S.M.D. receives in kind research support from Novo Nordisk and personal consulting fees, outside the scope of the current research. D.C. receives consulting fees from Roche Diagnostics and Trimedics, and speaker fees from Servier and BMS/Pfizer. M.K. receives consulting fees from Roche Diagnostics. N.A.M. reports involvement in clinical trials with Amgen, Ionis, Pfizer, Novartis and AstraZeneca without personal fees, payments or increase in salary. C.T.R. provides consultancies with Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen and Pfizer. M.S.S. provides Consultancies with Amgen, Anthos Therapeutics, AstraZeneca, Bristol Myers Squibb, DalCor, Dr. Reddy’s Laboratories, IFM Therapeutics, Intarcia, Merck, Moderna, Novo Nordisk and Silence Therapeutics. R.S. has received lecture fees and advisory board fees from BMS/Pfizer outside this work. L.M.R. is a consultant for the TOPMed Administrative Coordinating Center through WeStat. M.K. reports personal fees from Bayer, Böhringer Ingelheim, Pfizer BMS, Daiichi Sankyo, Medtronic, Biotronik, Boston Scientific, Johnson & Johnson and Roche, and grants from Bayer, Pfizer, Boston Scientific, BMS, Biotronik and Daiichi Sankyo. L.-C.W. has received research support from IBM to the Broad Institute. C.R. is supported by a grant from Bayer to the Broad Institute focused on the development of therapeutics for cardiovascular disease. The remaining authors declare no competing interests.

References

    1. Kornej, J., Börschel, C. S., Benjamin, E. J. & Schnabel, R. B. Epidemiology of atrial fibrillation in the 21st Century: novel methods and new insights. Circ. Res. 127, 4–20 (2020). - PubMed - PMC - DOI
    1. Benjamin, E. J. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98, 946–952 (1998). - PubMed - DOI
    1. Tanaka, Y. et al. Trends in cardiovascular mortality related to atrial fibrillation in the United States, 2011 to 2018. J. Am. Heart Assoc. 10, e020163 (2021). - PubMed - PMC - DOI
    1. Weng, L. C. et al. Heritability of atrial fibrillation. Circ. Cardiovasc. Genet. 10, e001838 (2017). - PubMed - PMC - DOI
    1. Roselli, C. et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nat. Genet. 50, 1225–1233 (2018). - PubMed - PMC - DOI

Publication types

Grants and funding